Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors

Pharmacogenetics

Volumn 9, Issue 4, 1999, Pages 477-489

  Ekins, Sean ^a,b   Bravi, Gianpaolo ^a,c   Binkley, Shelly ^a   Gillespie, Jennifer S ^a   Ring, Barbara J ^a   Wikel, James H ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

3D QSAR; Catalyst(TM); CYP2D6 inhibition; MS WHIM

Indexed keywords

BUFURALOL; DEBRISOQUINE 4 HYDROXYLASE; ENZYME INHIBITOR;

ARTICLE; COMPETITIVE INHIBITION; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG INTERACTION; HUMAN; HUMAN TISSUE; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; KINETICS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032849040     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Ackland M, Hyland R, Jones B, Tyman C, Smith D. The interaction of terfenadine with CYP2D6: an in vitro and molecular modelling study. Br J Clin Pharmacol 1998; 45:513P.
2. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989; 28:166-170.
3. Baroni M, Costantino G, Cruciani G, Riganelli D, Valigi R, Clementi S. Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant Struct Act Rel 1993; 12:9-20.
4. Bravi G, Gancia E, Mascani P, Pegna M, Todeschini R, Zaliani A. MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: a comparative 3D QSAR study in a series of steroids. J Comp Aided Mol Des 1997; 11:79-92.
5. Bravi G, Wikel JH. Application of MS-WHIM Descriptors: 1. Introduction of new molecular surface properties and 2. Prediction of binding affinity data. Quant Struct Act Rel 1999a; in press.
6. Bravi G, Wikel JH. Application of MS-WHIM Descriptors: 3. Prediction of molecular properties. Quant Struct Act Rel 1999b; in press.
7. Brosen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monitoring 1996; 18:393-396.
8. Cramer RDI, DePriest SA, Patterson DE, Hecht P. The developing practice of CoMFA. In: Kubinyi H, editor. 3D-QSAR in drug design: theory, methods and applications. Leiden, The Netherlands: ESCOM; 1993. pp. 443-445.
9. de Groot MJ, Bijloo GJ, Martens BJ, van Acker FAA, Vermeulen NPA. A refined substrate model for human cytochrome P450 2D6. Chem Res Toxicol 1997a; 10:41-48.
10. de Groot MJ, Bijloo GJ, Van Acker FAA, Fonseca Guerra C, Snijders JG, Vermeulen NPE. Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica 1997b; 27:357-368.
11. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, VandenBranden M, et al. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J Pharmacol Exp Ther 1999; 288:21-29.
12. Ferrari S, Leeman T, Dayer P. The role of lipophilicity in the inhibition of polymorphic cytochrome P450HD6 oxidation by beta-blocking agents in vitro. Life Sci 1991; 48:2259-2265.
13. Fuhr U, Strobl G, Manaut F, Anders E-M, Sorgel F, Lopez-de-brinas E, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993; 43:191-199.
14. Halliday RC, Jones BC, Park BK, Smith DA. Synthetic strategies to lower affinity for CYP2D6. Eur J Drug Metab Pharm 1997; 22:291-294.
15. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26:536-539.
16. Islam SA, Wolf CR, Lennard MS, Sternberg JE. A three dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 1991; 12:2211-2219.
17. Jones JP. He M, Trager WF, Rettie AE. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 1996: 24:1-6.
18. Klein CDP, Hopfinger AJ. Pharmacological activity and membrane interactions of antiarrhythmics: 4D-QSAR/QSPR analysis. Pharm Res 1998; 15:303-311.
19. Ko J-W, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25:853-862.
20. Koymans L, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 1992; 5:211-219.
21. Koymans LMH, Vermeulen NPE, Baarslag A, Donne-Op den Kelder GM. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Comp Aided Mol Des 1993; 7:281-289.
22. Kronback T, Mathys D, Gut J, Catin T, Meyer U. High performance liquid chromatography assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987; 162:24-32.
23. Kumar GI, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor (ABT-538) in human liver microsomes. J Pharmacol Exp Toxicol 1996; 277:423-431.
24. Lewis DFV. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica 1995; 25:333-366.
25. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997; 27:319-340.
26. Lin JH, Lu AYH. Inhibition of cytochrome P-450 and implications in drug development. Ann Rep Med Chem 1997:32:295-304.
27. Mackman R, Tschirret-Guth RA, Smith G, Hayhurst GP, Ellis SW, Lennard MS, et al. Active-site topologies of human CYP2D6 and its aspartate-301-glutamate, asparagine, and glycine mutants. Arch Biochem Biophys 1996: 331:134-140.
28. Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T. The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 1986; 16:449-464.
29. Modi S, Paine MJ, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, Roberts GCK. A model for human cytochrome P4502D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 1996; 35:4540-4550.
30. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-409.
31. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors. Clin Pharmacol Ther 1994; 55:141 P1-71.
32. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3 A catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995; 275:1131-1135.
33. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41:181-186.
34. Rodrigues AD, Roberts EM. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos 1997; 25:651-655.
35. Russell AL, Abernethy L. Identification of the cytochrome P450 isoforms involved in the metabolism of EMD 68 843. ISSX Proceed 1997; 12:61.
36. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
37. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34:256-261.
38. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995; 27:397-417.
39. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266:964-971.
40. Strobl GR, von Kruedener S, Stockigt J, Guengerich FP, Wolff T. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem 1993; 36:1136-1145.
41. van der Hoeven TA, Coon M. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P450-reductase from rabbit liver microsomes. J Biol Chem 1974; 249:6302-6310.
42. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996; 6:81-91.
43. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268:1278-1283.
44. Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15:125-131.
45. Weininger D. SMILES 1. Introduction and encoding rules. J Chem Inf Comput Sci 1988; 28:31-36.
46. Wold S, Johansson E, Cocchi M. PLS-Partial least squares projections to latent structures. In: Kubinyi H, editor. 3D-QSAR in drug design: theory, methods and applications. Leiden, The Netherlands: ESCOM; 1993. pp. 523-550.
47. Wolff T, Distelrath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, et al. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochmical inhibition and chemical modeling. Cancer Res 1985; 45:2116-2122.
48. Wrighton SA, Stevens JC. The humnn hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22:1-21.
49. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53:1605-1612.